UNSPSC 51263135: Tertatolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C16H25NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9ZO341YQXP, chemically known as 2-propanol, 1-((3,4-dihydro-2h-1-benzothiopyran-8-yl)oxy)-3-((1,1-dimethylethyl)amino)- but generally known as tertatolol, which bears US NIH Compound Identifier 36920. European Medicines Agency schedules Tertatolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10933MIG.

UNSPSC 51263135 Tertatolol is a Commodity code that nominally classifies a specific beta-blocker pharmaceutical product, but the recent state and local procurement activity tagged to this code does not reflect pharmaceutical acquisition. Instead, Seminole County, Florida posted an IFB for Naloxone and Safe Drug Deactivation Systems — products unrelated to tertatolol's scope. The mismatch suggests either a coding error in the county's procurement system or that this Commodity code is not actively used for its intended pharmaceutical application in state and local contracting. The single recent opportunity shows a county health department acquiring harm-reduction and opioid-response supplies through competitive sealed bidding, with standard insurance, E-Verify, and drug-free workplace compliance requirements.

Seminole County, Florida represents the only recent activity visible under this code, with an IFB (60459723LAS) posted June 30, 2026, for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, due July 26, 2023, and delivered quarterly to the Seminole County Community Health Building in Sanford. The procurement includes a two-year initial term with one-year renewal option and flags potential FEMA funding with associated federal regulatory requirements. Given the absence of additional opportunities and the apparent misalignment between the code's nominal scope and actual solicitation content, this code shows minimal relevant recent activity for business development purposes under its pharmaceutical taxonomy designation.